Clinipace brings on medical and development officers, along with a new brand

Boardroom
The CRO's new branding, “Challenge Accepted,” aims to illustrate its willingness to provide a personalized approach to sponsors and clients. (Pixabay)

Clinipace is bringing on new members of its C-suite to build out its role as a midsized contract research organization, after appointing a new CEO last fall.

In addition, the Morrisville, North Carolina-based CRO has launched a new brand with the tagline “Challenge Accepted,” to illustrate its willingness to provide a personalized approach to sponsors.

The new staff includes Sharon Moore, M.D., as chief medical officer and Dawn Sauro as chief development officer. Moore previously served as chief medical and safety officer of U.K. CRO Chiltern, which was acquired by LabCorp and Covance last year for $1.2 billion. She also served as an executive VP covering quality, medical and regulatory affairs.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

Sauro will be responsible for Clinipace’s partnership strategies and site relationships. She joins from the Sarah Cannon Research Institute, where she served as president for development innovations. Prior to that, Sauro was VP and general manager of oncology at inVentiv Health Clinical, VP of operations at PRA International and director of clinical operations at PPD.

RELATED: LabCorp snaps up Chiltern in $1.2B cash buy

“We want to be known as a solutions provider that has a personal interest in our customers’ success,” said Jason Monteleone, who became Clinipace’s CEO in October 2017. “And we are making the technology and talent investments to support that type of partnership with our clients.”

The latest round of appointments increases the CRO’s expertise in new therapeutic areas and analytics, the company said in a statement.

RELATED: Clinipace CEO, founder steps aside, hands reins over to new blood

Monteleone took over for founder Jeff Williams, who served as president and CEO of Clinipace for 14 years. Williams transitioned to an advisory role within the board of directors.

“After seeing him in action as a consultant to Clinipace over the last several months, I am confident he will build successfully on our company’s 14-year history and lead us into its next phase of growth,” Williams said at the time. Monteleone founded Pivotal Financial Consulting, a CRO-focused consulting firm.

Over the past few years, Clinipace has bought up several international CROs, including European organization Accovion and Hong Kong CRO Choice Pharma, as well as Paragon Biomedical, PFC Pharma, Regulus Pharmaceutical and Worldwide Clinical Research. Clinipace now totals over 800 staffers and has completed more than 1,500 clinical trials.